Trial · NCT00422058
Outcomes20
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 20
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mean Change From Baseline in Body Weight at Week 20 | Week 0, week 20 | ITT (intention to treat) analysis set using LOCF (last observation carried forward) is all randomised and exposed subjects from the double-blind period, who have been exposed to at least one dose of trial product. | kg | MEAN |
| SECONDARY | Mean Change From Baseline in Body Weight at Week 104 | Week 0, week 104 | ITT (intention to treat) analysis set using LOCF (last observation carried forward) is all randomised and exposed subjects from the double-blind period, who have been exposed to at least one dose of trial product. | kg | MEAN |
| SECONDARY | Change From Baseline in Fasting Plasma Glucose at Week 20 | Week 0, week 20 | ITT (intention to treat) analysis set using (LOCF) last observation carried forward is all randomised and exposed subjects from the double-blind period, who have been exposed to at least one dose of trial product | mmol/L | MEAN |
| SECONDARY | Change From Baseline in Fasting Plasma Glucose at Week 104 | Week 0, week 104 | ITT (intention to treat) analysis set using (LOCF) last observation carried forward is all randomised and exposed subjects from the double-blind period, who have been exposed to at least one dose of trial product | mmol/L | MEAN |
| SECONDARY | Change From Baseline in Fasting Insulin at Week 20 | Week 0, week 20 | ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied). | pmol/L | MEAN |
| SECONDARY | Change From Baseline in Fasting Insulin at Week 104 | Week 0, week 104 | ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied). | pmol/L | MEAN |
| SECONDARY | Change From Baseline in HbA1c (Glycosylated Haemoglobin A1c) at Week 20 | Week 0, week 20 | ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied). | percentage (%) of total haemoglobin | MEAN |
| SECONDARY | Change From Baseline in HbA1c (Glycosylated Haemoglobin A1c) at Week 104 | Week 0, week 104 | ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied). | percentage (%) of total haemoglobin | MEAN |
| SECONDARY | Change From Baseline in hsCRP (Highly Sensitive C-reactive Protein) at Week 20 | Week 0, week 20 | ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied). | mg/L | MEAN |
| SECONDARY | Change From Baseline in hsCRP (Highly Sensitive C-reactive Protein) at Week 104 | Week 0, week 104 | ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied). | mg/L | MEAN |
| SECONDARY | Change From Baseline in PAI-1 (Plasminogen Activator Inhibitor 1) at Week 20 | Week 0, week 20 | ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied). | U/mL | MEAN |
| SECONDARY | Change From Baseline in PAI-1 (Plasminogen Activator Inhibitor 1) at Week 104 | Week 0, week 104 | ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied). | U/mL | MEAN |
| SECONDARY | Change From Baseline in Fibrinogen at Week 20 | Week 0, week 20 | ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied). | g/L | MEAN |
| SECONDARY | Change From Baseline in Fibrinogen at Week 104 | Week 0, week 104 | ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied). | g/L | MEAN |
| SECONDARY | Change From Baseline in Adiponectin at Week 20 | Week 0, week 20 | ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied). | mcg/mL | MEAN |
| SECONDARY | Change From Baseline in Adiponectin at Week 104 | Week 0, week 104 | ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied). | mcg/mL | MEAN |
| SECONDARY | Change From Baseline in Waist Circumference at Week 20 | Week 0, week 20 | ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied). | cm | MEAN |
| SECONDARY | Change From Baseline in Waist Circumference at Week 104 | Week 0, week 104 | ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied). | cm | MEAN |
| SECONDARY | Change From Baseline in Blood Pressure at Week 20 | Week 0, week 20 | ITT (intention to treat) analysis set using (LOCF) last observation carried forward is all randomised and exposed subjects from the double-blind period, who have been exposed to at least one dose of trial product | mmHg | MEAN |
| SECONDARY | Change From Baseline in Blood Pressure at Week 104 | Week 0, week 104 | ITT (intention to treat) analysis set using (LOCF) last observation carried forward is all randomised and exposed subjects from the double-blind period, who have been exposed to at least one dose of trial product | mmHg | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00422058/outcomes